NL940005I1 - Remming van het infecterende vermogen in vitro en het cytopatische effect van htlv-iii/lav door 2,3-didesoxyinosine, 2,3-didesoxyguanosine of 2,3-didesoxyadenosine - Google Patents

Remming van het infecterende vermogen in vitro en het cytopatische effect van htlv-iii/lav door 2,3-didesoxyinosine, 2,3-didesoxyguanosine of 2,3-didesoxyadenosine

Info

Publication number
NL940005I1
NL940005I1 NL940005C NL940005C NL940005I1 NL 940005 I1 NL940005 I1 NL 940005I1 NL 940005 C NL940005 C NL 940005C NL 940005 C NL940005 C NL 940005C NL 940005 I1 NL940005 I1 NL 940005I1
Authority
NL
Netherlands
Prior art keywords
dideoxyguanosine
dideoxyadenosine
dideoxyinosine
htlv
iii
Prior art date
Application number
NL940005C
Other languages
English (en)
Other versions
NL940005I2 (nl
Original Assignee
Us Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25084165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL940005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Commerce filed Critical Us Commerce
Publication of NL940005I1 publication Critical patent/NL940005I1/nl
Publication of NL940005I2 publication Critical patent/NL940005I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
NL940005C 1985-08-26 1994-04-06 Remming van het infecterende vermogen in vitro en het cytopatische effect van HTLV-III/LAV door 2',3'-didesoxyinosine, 2',3'-didesoxyadenosine NL940005I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76901685A 1985-08-26 1985-08-26

Publications (2)

Publication Number Publication Date
NL940005I1 true NL940005I1 (nl) 1994-05-16
NL940005I2 NL940005I2 (nl) 1999-08-02

Family

ID=25084165

Family Applications (1)

Application Number Title Priority Date Filing Date
NL940005C NL940005I2 (nl) 1985-08-26 1994-04-06 Remming van het infecterende vermogen in vitro en het cytopatische effect van HTLV-III/LAV door 2',3'-didesoxyinosine, 2',3'-didesoxyadenosine

Country Status (16)

Country Link
US (1) US4861759A (nl)
EP (1) EP0216510B1 (nl)
JP (1) JPS62501712A (nl)
AT (1) ATE96325T1 (nl)
AU (1) AU570853B2 (nl)
CA (1) CA1269044A (nl)
CY (1) CY1792A (nl)
DE (1) DE3689220T2 (nl)
HK (1) HK47694A (nl)
IE (1) IE64518B1 (nl)
IL (1) IL79700A (nl)
LU (1) LU88475I2 (nl)
MX (1) MX9203377A (nl)
NL (1) NL940005I2 (nl)
NZ (1) NZ217185A (nl)
WO (1) WO1987001284A1 (nl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512330D0 (en) * 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US5495010A (en) * 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
US5028595A (en) * 1987-09-18 1991-07-02 Hoffmann-La Roche Inc. Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
EP0374096B1 (de) * 1988-12-14 1992-12-02 Ciba-Geigy Ag 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
IL93682A (en) * 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
NZ232912A (en) * 1989-03-17 1992-06-25 Oncogen Ltd Lp Synergistic composition of nucleoside derivatives for inhibiting hiv
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5571839A (en) * 1989-04-28 1996-11-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) D-aspartic acid β-hydroxamate for the treatment of viral infections and tumors
JPH04501857A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
US6207650B1 (en) * 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5268389A (en) * 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5221611A (en) * 1991-06-19 1993-06-22 Sigma Chemical Company Ddi immunoassays, derivatives, conjugates and antibodies
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
ATE273700T1 (de) * 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
WO1995017875A2 (en) * 1993-12-20 1995-07-06 Compagnie De Developpement Aguettant MIXTURES OF DIDEOXYNUCLEOSIDES AND D-ASPARTIC ACID β-HYDROXAMATE FOR INHIBITING RETROVIRAL SPREAD
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
CA2189097A1 (en) 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2000136136A (ja) * 1998-10-30 2000-05-16 Fujirebio Inc 抗ウイルス剤
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
CA2270600A1 (en) 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
RU2172632C1 (ru) * 2000-12-01 2001-08-27 Каплина Элли Николаевна Способ получения иммунотропного противовирусного препарата
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4112221A (en) * 1974-07-17 1978-09-05 Asahi Kasei Kogyo Kabushiki Kaisha Process for preparing 8,2'-O-anhydropurine nucleosides
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS59104399A (ja) * 1982-12-03 1984-06-16 Takeda Chem Ind Ltd ヌクレオチドおよびヌクレオシドの相互分離方法
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.

Also Published As

Publication number Publication date
EP0216510A3 (en) 1989-08-02
DE3689220D1 (de) 1993-12-02
IL79700A (en) 1991-09-16
ATE96325T1 (de) 1993-11-15
MX9203377A (es) 1992-09-01
AU570853B2 (en) 1988-03-24
IE64518B1 (en) 1995-08-09
JPH0215523B2 (nl) 1990-04-12
CY1792A (en) 1995-10-20
LU88475I2 (fr) 1994-09-09
IE940570L (en) 1987-02-26
NZ217185A (en) 1990-03-27
IE862265L (en) 1987-02-26
EP0216510A2 (en) 1987-04-01
IL79700A0 (en) 1986-11-30
JPS62501712A (ja) 1987-07-09
US4861759A (en) 1989-08-29
EP0216510B1 (en) 1993-10-27
DE3689220T2 (de) 1994-02-24
CA1269044A (en) 1990-05-15
WO1987001284A1 (en) 1987-03-12
AU6196886A (en) 1987-03-24
NL940005I2 (nl) 1999-08-02
HK47694A (en) 1994-05-20

Similar Documents

Publication Publication Date Title
NL940005I1 (nl) Remming van het infecterende vermogen in vitro en het cytopatische effect van htlv-iii/lav door 2,3-didesoxyinosine, 2,3-didesoxyguanosine of 2,3-didesoxyadenosine
DE68929398T2 (de) Erzeugung der zweiten Harmonischen
DE69031856T2 (de) Kompensation von lithographischen und Ätznäheeffekten
NO167213C (no) Komposittartikkel i form av en innlukningsgjenstand, samtfremgangsmaate for sulfonering av den innvendige overflateav en innlukningsgjenstand.
BE878501A (nl) Rolstoel of dergelijke
NL940019I1 (nl) Remming van het infecterende karakter in vitro en het cytopatische effect van htlv-iii/lav door 2',3'-didesoxycytidine
FI875353A (fi) Cytostatiskt verkande antracyklinderivat.
DE3473272D1 (en) Guanine derivatives, compositions containing them, and their anti-viral use
DE3674619D1 (de) Zusammensetzung fuer baeder auf basis von psoralen in der behandlung von psoriasis.
ATE45724T1 (de) Okuloselektive betablocker.
SE8600778D0 (sv) Chrystalline form of 7-(dimethylaminoethylene)-amino-9a-methoxymitosane
IT8420712A1 (it) "Trattamento delle infezioni erpetiche"
BR5901803U (pt) Desagregador de esterco em aviarios
PL208128A1 (pl) Sposob napedu i ustalania polozen stolow dwustanowiskowych
FI880688A0 (fi) Anordning foer att underlaetta taendning som sker med taendsticka.
IT1158953B (it) Processo per la funzionalizzazione di substrati aromatici ed eterociclici
PL209795A1 (pl) Sposob poprawiania biernej stabilnosci mocy laserow o pracy ciaglej
NO873220D0 (no) Fremgangsmaate og anlegg for noeytralisering av sur roek utviklet i saerdeleshet ved forbrenning av avfall.
ES294947Y (es) Dispositivo acondicionador-expositor de articulos perfeccionado
BR8701220A (pt) Processo para fabricacao de adesivos para o corpo e tambem para roupas em geral
KR890004715U (ko) 유모차 바퀴의 정지와 진행 방향을 고정하는 장치